You are here

FDA Approves Once-Daily Osmolex ER for Parkinson’s Disease Treatment

Tablets are also indicated to treat drug-induced extrapyramidal reactions

The FDA has approved an amantadine extended-release tablet (Osmolex ER, Osmotica Pharmaceutical) for the treatment of Parkinson’s disease and for the treatment of drug-induced extrapyramidal reactions in adults. Extrapyramidal symptoms are known side effects of many common medications.

Osmolex ER tablets are a proprietary drug formulation containing a combination of immediate-release and extended-release amantadine utilizing Osmotica’s patented Osmodex technology. The tablet is taken once-daily in the morning, releasing amantadine throughout the day. Physicians have three dosage options with 129-mg, 193-mg, and 258-mg tablets, with a maximum daily dose of 322 mg.

Osmolex ER is protected by three formulation patents with protection extending through March 2030, with additional patent applications pending.

Source: Osmotica; February 19, 2018.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress